HC Wainwright Issues Pessimistic Estimate for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at HC Wainwright dropped their Q4 2024 earnings estimates for ACADIA Pharmaceuticals in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings of $0.14 per share for the quarter, down from their previous estimate of $0.23. HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.54 EPS.

A number of other research analysts have also weighed in on ACAD. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald dropped their price target on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 7th. Royal Bank of Canada decreased their price objective on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an "outperform" rating for the company in a report on Wednesday, August 7th. StockNews.com upgraded ACADIA Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, September 13th. Finally, Raymond James reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $25.56.

ACADIA Pharmaceuticals Trading Up 2.7 %

Shares of ACAD traded up $0.46 during trading hours on Friday, reaching $17.66. The stock had a trading volume of 1,533,532 shares, compared to its average volume of 1,689,971. The firm has a 50-day simple moving average of $15.45 and a 200 day simple moving average of $15.98. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $32.59. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of 98.11 and a beta of 0.38.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. During the same period in the prior year, the business earned ($0.40) EPS. The firm's revenue for the quarter was up 18.3% on a year-over-year basis.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Park Place Capital Corp bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter valued at about $25,000. Values First Advisors Inc. purchased a new stake in ACADIA Pharmaceuticals during the third quarter valued at about $27,000. Covestor Ltd lifted its stake in ACADIA Pharmaceuticals by 70.5% during the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 840 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of ACADIA Pharmaceuticals in the 1st quarter worth about $48,000. Finally, Quest Partners LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 1,047 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the company's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares of the company's stock, valued at $797,264.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Mark C. Schneyer sold 9,733 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $148,720.24. Following the completion of the transaction, the chief financial officer now directly owns 43,735 shares in the company, valued at approximately $668,270.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Brendan Teehan sold 9,534 shares of the company's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the sale, the chief operating officer now owns 52,177 shares in the company, valued at approximately $797,264.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,014 shares of company stock worth $779,494. 28.30% of the stock is owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.